Literature DB >> 31316786

Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry.

Cesare Cremon1, Marilia Carabotti2, Rosario Cuomo3, Fabio Pace4, Paolo Andreozzi3, Maria Raffaella Barbaro1, Bruno Annibale2, Giovanni Barbara1.   

Abstract

Background: Although diverticular disease is a common condition, its effective treatment is challenging in clinical practice. Objective: The objective of this article is to assess pharmacological management in different clinical settings of diverticular disease and factors associated with treatment using the Italian registry Registro Malattia Diverticolare (REMAD).
Methods: At study enrolment, patients were categorised into subgroups: diverticulosis, symptomatic uncomplicated diverticular disease and previous diverticulitis. We registered demographic, clinical and lifestyle factors, quality of life and the use of treatments for diverticular disease in the last year. Logistic regression analysis assessed the association between clinical factors and treatment consumption.
Results: A total of 500 of the 1206 individuals included had had at least one treatment for diverticular disease in the last year: 23.6% (166/702) of patients with diverticulosis, 55.9% (165/295) of patients with symptomatic diverticular disease, and 80.9% (169/209) of patients with previous diverticulitis (p < 0.001). In multivariate analysis, the following factors were significantly associated with treatment use: female gender, family history of colonic diverticula, organic digestive comorbidity and impaired physical quality of life components.
Conclusion: Individuals with diverticular disease take medications based on the different clinical settings of disease. We identified different features associated with treatment use in the distinct clinical entities of diverticular disease.ClinicalTrial.gov Identifier: NCT03325829.

Entities:  

Keywords:  Diverticulosis; management; pharmacological treatments; previous diverticulitis; registry; symptomatic uncomplicated diverticular disease

Year:  2019        PMID: 31316786      PMCID: PMC6620876          DOI: 10.1177/2050640619845990

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  37 in total

1.  The quality of life in patients with chronic pancreatitis evaluated using the SF-12 questionnaire: a comparative study with the SF-36 questionnaire.

Authors:  R Pezzilli; A M Morselli-Labate; L Frulloni; G M Cavestro; B Ferri; G Comparato; L Gullo; R Corinaldesi
Journal:  Dig Liver Dis       Date:  2005-10-19       Impact factor: 4.088

2.  Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.

Authors:  M Bianchi; V Festa; A Moretti; A Ciaco; M Mangone; V Tornatore; A Dezi; R Luchetti; B De Pascalis; C Papi; M Koch
Journal:  Aliment Pharmacol Ther       Date:  2011-03-02       Impact factor: 8.171

3.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

Authors:  J Ware; M Kosinski; S D Keller
Journal:  Med Care       Date:  1996-03       Impact factor: 2.983

4.  Italian consensus conference for colonic diverticulosis and diverticular disease.

Authors:  Rosario Cuomo; Giovanni Barbara; Fabio Pace; Vito Annese; Gabrio Bassotti; Gian Andrea Binda; Tino Casetti; Antonio Colecchia; Davide Festi; Roberto Fiocca; Andrea Laghi; Giovanni Maconi; Riccardo Nascimbeni; Carmelo Scarpignato; Vincenzo Villanacci; Bruno Annibale
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 5.  Diagnostic challenges of symptomatic uncomplicated diverticular disease.

Authors:  Cesare Cremon; Lara Bellacosa; Maria R Barbaro; Rosanna F Cogliandro; Vincenzo Stanghellini; Giovanni Barbara
Journal:  Minerva Gastroenterol Dietol       Date:  2017-01-12

Review 6.  Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review.

Authors:  Giovanni Maconi; Giovanni Barbara; Cristina Bosetti; Rosario Cuomo; Bruno Annibale
Journal:  Dis Colon Rectum       Date:  2011-10       Impact factor: 4.585

7.  Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment?

Authors:  Giuseppe Comparato; Libera Fanigliulo; Giovanni Aragona; Giulia M Cavestro; Lucas G Cavallaro; Gioacchino Leandro; Alberto Pilotto; Giorgio Nervi; Paolo Soliani; Mario Sianesi; Angelo Franzé; Francesco Di Mario
Journal:  Dig Dis       Date:  2007       Impact factor: 2.404

8.  Burden of gastrointestinal disease in the United States: 2012 update.

Authors:  Anne F Peery; Evan S Dellon; Jennifer Lund; Seth D Crockett; Christopher E McGowan; William J Bulsiewicz; Lisa M Gangarosa; Michelle T Thiny; Karyn Stizenberg; Douglas R Morgan; Yehuda Ringel; Hannah P Kim; Marco Dacosta DiBonaventura; Charlotte F Carroll; Jeffery K Allen; Suzanne F Cook; Robert S Sandler; Michael D Kappelman; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

9.  The role of colonic mast cells and myenteric plexitis in patients with diverticular disease.

Authors:  Gabrio Bassotti; Vincenzo Villanacci; Riccardo Nascimbeni; Elisabetta Antonelli; Moris Cadei; Stefania Manenti; Luisa Lorenzi; Amin Titi; Bruno Salerni
Journal:  Int J Colorectal Dis       Date:  2012-08-05       Impact factor: 2.571

Review 10.  Treatment of diverticular disease: an update on latest evidence and clinical implications.

Authors:  Marilia Carabotti; Bruno Annibale
Journal:  Drugs Context       Date:  2018-03-21
View more
  1 in total

Review 1.  Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review).

Authors:  M Carabotti; B Annibale
Journal:  Tech Coloproctol       Date:  2019-07-25       Impact factor: 3.781

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.